Research article · 15 Apr 2026
Research articlePublished 2015
Acute Kidney Injury Hyperkalemia in Patients Undergoing Renin-Angiotensin-Aldosterone Blockade
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: In order to minimize the risk of hyperkalemia (hK+) in patients with heart failure (HF), in 2005 and 2009 ACC/AHA (American College of Cardiology; American Heart Association) joint guidelines recommended associating renin-angiotensin system (RAS) inhibition with low-dose ALD-block in patients with serum creatinine (sCr) less than 2.5 mg/dl and serum potassium (sK+) lower than 5 mEq/l. A prevalence of HF in individuals aged 65 and over with mild renal failure at risk of hyperkalemia is steeply increasing. Such data has persuaded us to analyze the association between over-65 HF standard treatment and hK+. Aim: This observational retrospective study analyzed emergency room admissions aged 65 and over undergoing ACEI with ALD-block or potassium sparing diuretics (K+-sparing) and hK+ (sK+ > 6 mEq/l) over a one year period, from January to December 2010. Methods: 8,407 over-65 emergency admissions of 62,348 adult entries have been selected from the hospital database. Data was matched with the Local Medical District pharmaceutical database with joint use of ACEI and ALDblock or K+-sparing medications. Acute Kidney Injury (AKI) was defined according to AKIN (Acute Kidney Injury Criteria) guidelines. Results: ACEI with spironolactone or K+-sparing was found in 332 (3.9%) out of the 8,407 over-65 emergency admissions. Seven HF patients (2.1% aged 79-82, 5F 2M) of 332 had hK+ (sK+, 6.3-8.5 mEq/l). Six patients had spironolactone and 1 K+-sparing treatment. sCr before admission was available in 3 (sCr, 1.1-1.4 mg/dl) out of 7 patients, all of which developed AKI. All 7 patients with hK+ received conservative medical treatment only. Conclusions: hK+ occurred in 7 (2.1%) out of the 332 HF over-65 emergency admissions on ACEI. It might suggest a strict application of the current ACC/AHA guidelines with a closer follow-up for those HF patients at risk of developing AKI and hK+.
Keywords
Subjects
Nephrology & UrologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Nephrology & Therapeutics.
Brief report · 30 Mar 2026
Renal Fibrosis: Targeting Pathways For New Therapies
Brief report · 30 Mar 2026
SGLT2 Inhibitors: A New Era for Diabetic Kidney Disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Nephrology & Therapeutics
- SubjectNephrology & Urology
- BylineArticles whose byline prints “Francesco Falaschi”
- BylineArticles whose byline prints “Lorena Fenoglio”
- BylineArticles whose byline prints “Mirosa Dellagiovanna”
- BylineArticles whose byline prints “Valentina de Vecchi”
- BylineArticles whose byline prints “Vincenzo Sepe”
- BylineArticles whose byline prints “Maria Antonietta Bressan”
